SCHEDULE 13D/A: Nant Capital and Patrick Soon-Shiong Secure Dominant Stake in Panbela Therapeutics Through $12 Million Convertible Note Investment

Nant Capital, LLC and Patrick Soon-Shiong have acquired the right to convert notes into 86.98% of Panbela Therapeutics, Inc.'s common stock, following a $12 million private placement of senior convertible promissory notes.

Summary

• Nant Capital, LLC and Patrick Soon-Shiong (the "Reporting Owners") have filed an Amendment No. 1 to their Schedule 13D, disclosing a significant increase in their beneficial ownership of Panbela Therapeutics, Inc.
• This stems from a Note Purchase Agreement entered into on October 22, 2024, where Panbela issued interest-bearing Senior Convertible Promissory Notes ("Notes") to Nant Capital.
• The Notes consist of a Tranche A Note for $2,850,000 issued on October 22, 2024, and a Tranche B Note for $9,150,000 issued on November 15, 2024, totaling $12,000,000 in cash proceeds to Panbela.
• Upon conversion of these Notes, Nant Capital has the right to acquire 32,432,432 shares of Panbela's Common Stock.
• This potential conversion represents approximately 86.98% of the Issuer's outstanding Common Stock, calculated based on 4,854,861 shares outstanding as of November 11, 2024, plus the 32,432,432 convertible shares.
• The transaction was conducted as a private placement, exempt from registration requirements.

Sentiment

Score: 7

Explanation: The capital injection of $12 million is a significant positive for Panbela Therapeutics, providing crucial funding. However, the substantial potential dilution for existing shareholders upon conversion of the notes introduces a negative aspect, leading to a moderately positive overall sentiment for the company's financial stability but a mixed outlook for current equity holders.

Positives

• Panbela Therapeutics, Inc. received a significant capital injection of $12,000,000 through the issuance of Senior Convertible Promissory Notes.
• The funding was secured via a private placement, indicating direct investor confidence.

Negatives

• The potential conversion of the Notes into 32,432,432 shares of common stock would result in substantial dilution for existing shareholders, reducing their ownership percentage to a minority stake.

Risks

• Significant shareholder dilution upon conversion of the Senior Convertible Promissory Notes, potentially reducing the value of existing common stock.

Future Outlook

The document does not contain explicit forward-looking statements or guidance beyond the potential conversion of notes.

Industry Context

This transaction represents a significant capital infusion for a biotechnology company, which often rely on external funding for research, development, and operational expenses. Such large investments from strategic partners or significant individual investors like Patrick Soon-Shiong can be crucial for a company's long-term viability and progression of its pipeline, especially in the absence of significant revenue streams.

Comparison to Industry Standards

• This is a specific capital raise and ownership disclosure, not a performance report. Therefore, direct comparison to industry-standard financial results or project outcomes is not applicable.
• Securing $12 million through convertible notes from a single investor (or related entities) is a substantial financing event for a company of Panbela's size (based on its current outstanding shares), potentially providing a runway for its operations.
• The resulting 86.98% beneficial ownership upon conversion indicates a near-complete change of control to the investor group, which is a significant event in any industry.

Related Party Transactions

• The transaction involves Nant Capital, LLC and Patrick Soon-Shiong acquiring a significant stake (potentially 86.98% upon conversion) in Panbela Therapeutics, Inc. through convertible notes. While not explicitly labeled as a "related party transaction" in the document, the substantial nature of the investment and the involvement of a prominent individual investor (Patrick Soon-Shiong) suggests a close relationship or the establishment of one, which could be viewed as a related party dealing.

Stakeholder Impact

• Shareholders: Existing shareholders face significant potential dilution of their ownership stake upon conversion of the notes, reducing their percentage of the company.
• Company (Panbela Therapeutics): Benefits from a substantial capital injection of $12 million, which can fund operations, research, and development.

Next Steps

• Potential conversion of the Senior Convertible Promissory Notes into common stock by Nant Capital.

Key Dates

Keywords

Panbela Therapeutics, Nant Capital, Patrick Soon-Shiong, Schedule 13D, convertible notes, private placement, beneficial ownership, capital raise, dilution, common stock, SEC filing